Long-Term Efficacy and Safety of Raltegravir, Etravirine, and Darunavir/Ritonavir in Treatment-Experienced Patients-Reference-Cited by-同舟云学术

Long-Term Efficacy and Safety of Raltegravir, Etravirine, and Darunavir/Ritonavir in Treatment-Experienced Patients

Published:2012-04-15 Issue:5 Volume:59 Page:489-493
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:

Author:

Fagard Catherine,Colin Céline,Charpentier Charlotte,Rami Agathe,Jacomet Christine,Yeni Patrick,Vittecoq Daniel,Katlama Christine,Molina Jean-Michel,Descamps Diane,Chêne Geneviève,Yazdanpanah Yazdan

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference10 articles.

1. . High rate of virologic suppression with raltegravir plus etravirine and darunavirritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.;Yazdanpanah;Clin Infect Dis,2009

2. . Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.;Markowitz;J Acquir Immune Defic Syndr,2007

3. . Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.;Lennox;Lancet,2009

4. . Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavirritonavir regimen.;Charpentier;AIDS,2010

5. . Once-daily atazanavirritonavir compared with twice-daily lopinavirritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.;Molina;J Acquir Immune Defic Syndr,2010

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real World Data of Viral Suppression With Darunavir/Cobicistat and Dolutegravir/Rilpivirine Among Treatment-Experienced Patients Living With Multidrug-Resistant HIV;Journal of Pharmacy Practice;2024-04-29

2. Pharmacotherapeutic Interventions in People Living With HIV Undergoing Solid Organ Transplantation: A Scoping Review;Transplantation Direct;2023-01-26

3. Long-term follow-up of HIV-1 multi-drug-resistant treatment-experienced participants treated with etravirine, raltegravir and boosted darunavir: towards drug-reduced regimen? ANRS CO3 Aquitaine Cohort 2007–2018;International Journal of Antimicrobial Agents;2023-01

4. The crosstalk between antiretrovirals pharmacology and HIV drug resistance;Expert Review of Clinical Pharmacology;2020-06-30

5. Successful Kidney Transplantation in a Recipient Coinfected with Hepatitis C Genotype 2 and HIV from a Donor Infected with Hepatitis C Genotype 1 in the Direct-Acting Antiviral Era;Case Reports in Hepatology;2020-01-30